Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.
暂无分享,去创建一个
[1] W. Woodward,et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[2] K. Barnum,et al. Prognostic and Predictive Biomarkers in Oligometastatic Disease , 2020, Cancer journal.
[3] C. Dooms,et al. Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion. , 2019, European journal of cancer.
[4] D. Planchard,et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] J. Aerts,et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.
[6] C. Langer,et al. Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. , 2019, JAMA oncology.
[7] J. Lee,et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Tafreshi,et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Bradley,et al. Combining stereotactic body radiation therapy with immunotherapy: current data and future directions. , 2018, Translational lung cancer research.
[10] N. Girard,et al. MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts , 2018, Journal of Thoracic Oncology.
[11] D. Planchard,et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.
[12] P. Solli,et al. Surgical approach in oligometastatic non-small cell lung cancer. , 2018, Annals of translational medicine.
[13] Arnaud Boyer,et al. Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. , 2018, Journal of thoracic disease.
[14] D. Landau,et al. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer , 2018, BMJ Open.
[15] P. Iyengar,et al. Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.
[16] Jedd D. Wolchok,et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.
[17] Sekine Yasuo,et al. 当院におけるoligometastatic non‐small cell lung cancerに関する検討 , 2016 .
[18] C. Drake,et al. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. , 2015, The Lancet. Oncology.
[19] W. Curran,et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.
[20] P. Iyengar,et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Ridder,et al. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] R. Doebele,et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. , 2014, International journal of radiation oncology, biology, physics.
[23] E. Scarpi,et al. Noninferiority Trials in Second-Line Treatments of Nonsmall Cell Lung Cancer: A Systematic Review of Literature With Meta-analysis of Phase III Randomized Clinical Trials , 2012, American journal of clinical oncology.
[24] P. Lambin,et al. Radical Treatment of Non–Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct01282450) , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[25] L. Tanoue,et al. Reduced lung cancer mortality with low-dose computed tomographic screening , 2011 .
[26] R. Weichselbaum,et al. MicroRNA Expression Characterizes Oligometastasis(es) , 2011, PloS one.
[27] E John Wherry,et al. T cell exhaustion , 2011 .
[28] Cancer Facts & Figures 2021 , 2010 .
[29] R. Abrams,et al. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[30] C. N. Coleman,et al. External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing , 2004, Cancer Research.
[31] M Buyse,et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. , 1997, The Journal of thoracic and cardiovascular surgery.
[32] D. Ettinger,et al. Metastatic non-small cell lung cancer , 1993 .
[33] Y Maruyama,et al. A randomized trial of surgery in the treatment of single metastases to the brain. , 1990, The New England journal of medicine.
[34] Peter Schlag,et al. Resection of the liver for colorectal carcinoma metastases , 1988, Diseases of the colon and rectum.